diazooxonorleucine

6-Diazo-5-oxo-L-norleucine
Systematic (IUPAC) name
	(5S)-5-Amino-1-diazonio-6-hydroxy-6-oxohex-1-en-2-olate
Clinical data
Legal status	not approved;
Identifiers
CAS Registry Number	157-03-9
PubChem	CID: 5359375
ChemSpider	16735775
ChEMBL	CHEMBL97485
Chemical data
Formula	C6H9N3O3
Molecular mass	171.15 g/mol
	SMILES O=C(CC[C@H](N)C(O)=O)\C=[N+]=[N-] ;
	InChI InChI=1S/C6H9N3O3/c7-5(6(11)12)2-1-4(10)3-9-8/h3,5H,1-2,7H2,(H,11,12)/t5-/m0/s1 ; Key:YCWQAMGASJSUIP-YFKPBYRVSA-N ;
(what is this?) (verify)

ジアゾオキソノルロイシン

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/07/05 21:19:04」(JST)

wiki en

[Wiki en表示]

6-Diazo-5-oxo-L-norleucine (DON) is a glutamine antagonist, which was isolated originally from Streptomyces in a sample of Peruvian soil. It is a non-standard amino acid. The diazo compound was characterized in 1956 by Henry W Dion et al.,^[2] who suggested a possible use in cancer therapy. This antitumoral efficacy was confirmed in different animal models.^[3] DON was tested as chemotherapeutic agent in different clinical studies, but was never approved. The last clinical results were published in 2008, though not as DON monotherapy but in combination with a recombinant glutaminase.^[4]

Chemistry

DON is a water soluble yellowish powder, which can be dissolved also in aqueous solutions of methanol, acetone or ethanol, but dissolution in absolute alcohols is difficult. Solutions of at least 50 µM DON in 0.9% NaCl are lightly yellowish. The crystalline form appears as yellowish greenish needles. The specific rotation is [α]₂₆^D +21° (c = 5.4% in H₂O). In phosphate buffer, pH 7 are the ultraviolet absorption maxima at 274 nm (E1%1 cm. 683) and 244 nm (E1%1 cm 376).^[2]^[5]

Biochemistry

DON is used as inhibitor of different glutamine utilizing enzymes. Due to its similarity to glutamine it can enter catalytic centres of these enzymes and inhibits them by covalent binding, or more precisely by alkylation.^[6]^[7] In the following table gives a survey of DON targets.

Selection of enzymes inhibited by DON
Enzyme	Metabolic pathway	References
Carbamoyl phosphate synthase (CAD)	Pyrimidine-De-Novo-Synthesis	^[6]^[8]
CTP synthase (CTPS)	Pyrimidine-De-Novo-Synthesis	^[6]^[8]
FGAR amidotransferase	Purine-De-Novo-Synthesis	^[6]^[9]
Guanosine monophosphate synthetase (GMPS)	Purine-De-Novo-Synthesis	^[6]^[10]
PRPP amidotransferase	Purine-De-Novo-Synthesis	^[6]^[10]
Mitochondrial glutaminase	First step of glutaminolysis	^[6]^[10]
NAD synthase	Coenzyme of the electron transport chain	^[6]^[11]
Asparagine synthetase	Amino acid synthesis	^[6]^[12]

Pharmacology

DON is a cytotoxic inhibitor of many enzymes of nucleotide synthesis. It could be shown in vitro that DON treatment led to apoptosis, the programmed cell death. Different pathways were investigated. So it could be shown that the inner mitochondrial membrane was damaged,^[13] and single strand DNA breaks were observed.^[14] The exact mode of action remains unclear and needs further research.

DON is not approved as pharmaceutical agent, but is tested in combination with a recombinant glutaminase in clinical trials for the treatment of different solid tumors.^[4]

References

^ PubChem Databank
^ ^a ^b Dion HW et al. (1954). "6-diazo-5-oxo-L-norleucine, A new tumor inhibitory substance. II: Isolation and Characterization". Antibiotics and Chemotherapy 78: 3075–7.
^ Yoshioka K, Takehara H, Okada A, Komi N (June 1992). "Glutamine antagonist with diet deficient in glutamine and aspartate reduce tumor growth". Tokushima J. Exp. Med. 39 (1–2): 69–76. PMID 1412455.
^ ^a ^b Mueller C, Al-Batran S, Jaeger E, Schmidt B, Bausch M, Unger C, Sethuraman N (2008). "A phase IIa study of PEGylated glutaminase (PEG-PGA) plus 6-diazo-5-oxo-L-norleucine (DON) in patients with advanced refractory solid tumors". J Clin Oncol 26 (May 20 Suppl): abstr 2533.
^ DeWald HA and Moore AM: 6-Diazo-5-oxo-L-norleucine, a new tumor-inhibitory substance. Preparation of L (D and L)-forms, in Am. Chem. Soc. Meeting, Dallas, 1956, p. 13M .
^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ Pinkus LM (1977). "Glutamine binding sites". Meth. Enzymol. Methods in Enzymology 46: 414–27. doi:10.1016/S0076-6879(77)46049-X. ISBN 978-0-12-181946-0. PMID 909432.
^ Ortlund E, Lacount MW, Lewinski K, Lebioda L (February 2000). "Reactions of Pseudomonas 7A glutaminase-asparaginase with diazo analogues of glutamine and asparagine result in unexpected covalent inhibitions and suggests an unusual catalytic triad Thr-Tyr-Glu". Biochemistry 39 (6): 1199–204. doi:10.1021/bi991797d. PMID 10684596.
^ ^a ^b Eidinoff ML, Knoll JE, Marano B, Cheong L (January 1957). "Pyrimidine Studies, I. Effect of DON (6-Diazo-5Oxo-L-Norleucine) on incorporation of precursors into nucleic acid pyrimidines" (PDF) 18 (1). pp. 105–9.
^ Levenberg B, Melnick I, Buchanan JM (1956). "Biosynthesis of the purines, XV. The effect of Aza-L-Serine and 6-Diazo-5-Oxo-L-Norleucine on inosinic acid biosynthesis de novo" (PDF). J Biol Chem 225 (1): 163–176. PMID 13416227.
^ ^a ^b ^c Ahluwalia GS, Grem JL, Hao Z, Cooney DA (1990). "Metabolism and action of amino acid analog anti-cancer agents". Pharmacol. Ther. 46 (2): 243–71. doi:10.1016/0163-7258(90)90094-I. PMID 2108451.
^ Barclay RK, Phillipps MA (February 1966). "Effects of 6-diazo-5-oxol-norleucine and other tumor inhibitors on the biosynthesis of nicotinamide adenine dinucleotide in mice". Cancer Res. 26 (2): 282–6. PMID 4285554.
^ Rosenbluth RJ, Cooney DA, Jayaram HN, Milman HA, Homan ER (August 1976). "DON, CONV and DONV-II. Inhibition of L-'asparagine synthetase in vivo". Biochem. Pharmacol. 25 (16): 1851–8. doi:10.1016/0006-2952(76)90189-1. PMID 9091.
^ Wu F, Lukinius A, Bergström M, Eriksson B, Watanabe Y, Långström B (July 1999). "A mechanism behind the antitumour effect of 6-diazo-5-oxo-L-norleucine (DON): disruption of mitochondria". Eur. J. Cancer 35 (7): 1155–61. doi:10.1016/S0959-8049(99)00099-4. PMID 10533463.
^ Hiramoto K, Fujino T, Kikugawa K (June 1996). "DNA strand cleavage by tumor-inhibiting antibiotic 6-diazo-5-oxo-L-norleucine". Mutat. Res. 360 (2): 95–100. doi:10.1016/0165-1161(95)00073-9. PMID 8649470.

English Journal

The detrimental effects of acute hyperglycemia on myocardial glucose uptake.

Joseph D1, Kimar C1, Symington B1, Milne R1, Essop MF2.
Life sciences.Life Sci.2014 Jun 6;105(1-2):31-42. doi: 10.1016/j.lfs.2014.04.009. Epub 2014 Apr 18.
AIMS: Although acute hyperglycemic (AHG) episodes are linked to lower glucose uptake, underlying mechanisms remain unclear. We hypothesized that AHG triggers reactive oxygen species (ROS) production and increases non-oxidative glucose pathway (NOGP) activation, i.e. stimulation of advanced glycation
PMID 24747137

Involvement of hyaluronan synthesis in ovarian follicle growth in rats.

Takahashi N1, Tarumi W, Ishizuka B.
Reproduction (Cambridge, England).Reproduction.2013 Dec 19;147(2):189-97. doi: 10.1530/REP-13-0464. Print 2014 Feb.
Most of the previous studies on ovarian hyaluronan (HA) have focused on mature antral follicles or corpora lutea, but scarcely on small preantral follicles. Moreover, the origin of follicular HA is unknown. To clarify the localization of HA and its synthases in small growing follicles, involvement o
PMID 24218629

Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation.

Erickson JR1, Pereira L, Wang L, Han G, Ferguson A, Dao K, Copeland RJ, Despa F, Hart GW, Ripplinger CM, Bers DM.
Nature.Nature.2013 Oct 17;502(7471):372-6. doi: 10.1038/nature12537. Epub 2013 Sep 29.
Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) is an enzyme with important regulatory functions in the heart and brain, and its chronic activation can be pathological. CaMKII activation is seen in heart failure, and can directly induce pathological changes in ion channels, Ca(2+) handling an
PMID 24077098

Japanese Journal

Amino acid sequence of the diazooxonorleucine binding site of Acinetobacter and Pseudomonas 7A glutaminase-asparaginase enzymes

Biochemistry 17, 411-417, 1978
NAID 80014948098

Related Pictures

Category:Diazo compounds - Wikimedia Commons Diazooxonorleucine; 6 diazo 5 oxo l norleucine; 6-diazo-5-oxo-l-norleucine

[PubChem-1] PubChem Databank

[Dion_HW-2] Dion HW et al. (1954). "6-diazo-5-oxo-L-norleucine, A new tumor inhibitory substance. II: Isolation and Characterization". Antibiotics and Chemotherapy 78: 3075–7.

[Yoshioka-3] Yoshioka K, Takehara H, Okada A, Komi N (June 1992). "Glutamine antagonist with diet deficient in glutamine and aspartate reduce tumor growth". Tokushima J. Exp. Med. 39 (1–2): 69–76. PMID 1412455.

[Mueller-4] Mueller C, Al-Batran S, Jaeger E, Schmidt B, Bausch M, Unger C, Sethuraman N (2008). "A phase IIa study of PEGylated glutaminase (PEG-PGA) plus 6-diazo-5-oxo-L-norleucine (DON) in patients with advanced refractory solid tumors". J Clin Oncol 26 (May 20 Suppl): abstr 2533.

[DeWald-5] DeWald HA and Moore AM: 6-Diazo-5-oxo-L-norleucine, a new tumor-inhibitory substance. Preparation of L (D and L)-forms, in Am. Chem. Soc. Meeting, Dallas, 1956, p. 13M .

[Pinkus-6] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ Pinkus LM (1977). "Glutamine binding sites". Meth. Enzymol. Methods in Enzymology 46: 414–27. doi:10.1016/S0076-6879(77)46049-X. ISBN 978-0-12-181946-0. PMID 909432.

[Ortlund-7] Ortlund E, Lacount MW, Lewinski K, Lebioda L (February 2000). "Reactions of Pseudomonas 7A glutaminase-asparaginase with diazo analogues of glutamine and asparagine result in unexpected covalent inhibitions and suggests an unusual catalytic triad Thr-Tyr-Glu". Biochemistry 39 (6): 1199–204. doi:10.1021/bi991797d. PMID 10684596.

[Eidinoff-8] Eidinoff ML, Knoll JE, Marano B, Cheong L (January 1957). "Pyrimidine Studies, I. Effect of DON (6-Diazo-5Oxo-L-Norleucine) on incorporation of precursors into nucleic acid pyrimidines" (PDF) 18 (1). pp. 105–9.

[Levenberg-9] Levenberg B, Melnick I, Buchanan JM (1956). "Biosynthesis of the purines, XV. The effect of Aza-L-Serine and 6-Diazo-5-Oxo-L-Norleucine on inosinic acid biosynthesis de novo" (PDF). J Biol Chem 225 (1): 163–176. PMID 13416227.

[Ahluwalia-10] Ahluwalia GS, Grem JL, Hao Z, Cooney DA (1990). "Metabolism and action of amino acid analog anti-cancer agents". Pharmacol. Ther. 46 (2): 243–71. doi:10.1016/0163-7258(90)90094-I. PMID 2108451.

[Barclay-11] Barclay RK, Phillipps MA (February 1966). "Effects of 6-diazo-5-oxol-norleucine and other tumor inhibitors on the biosynthesis of nicotinamide adenine dinucleotide in mice". Cancer Res. 26 (2): 282–6. PMID 4285554.

[Rosenbluth-12] Rosenbluth RJ, Cooney DA, Jayaram HN, Milman HA, Homan ER (August 1976). "DON, CONV and DONV-II. Inhibition of L-'asparagine synthetase in vivo". Biochem. Pharmacol. 25 (16): 1851–8. doi:10.1016/0006-2952(76)90189-1. PMID 9091.

[Wu-13] Wu F, Lukinius A, Bergström M, Eriksson B, Watanabe Y, Långström B (July 1999). "A mechanism behind the antitumour effect of 6-diazo-5-oxo-L-norleucine (DON): disruption of mitochondria". Eur. J. Cancer 35 (7): 1155–61. doi:10.1016/S0959-8049(99)00099-4. PMID 10533463.

[Hiramoto-14] Hiramoto K, Fujino T, Kikugawa K (June 1996). "DNA strand cleavage by tumor-inhibiting antibiotic 6-diazo-5-oxo-L-norleucine". Mutat. Res. 360 (2): 95–100. doi:10.1016/0165-1161(95)00073-9. PMID 8649470.

匿名

検索

案内

案内